
Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.
Wailea, Maui. - Age is an important variable in the diagnosis of contact dermatitis, said Suzanne M. Connolly, M.D., associate professor of dermatology, Mayo Clinic, Scottsdale, Ariz.